NanoBio gets 3.2M, spins off NanoCure

Dec. 22, 2003 — NanoBio Corp., an Ann Arbor, Mich.-based firm specializing in nanotechnology-based pharmaceuticals, announced it has received a $3.2 million federal contract and is spinning off a company.


The U.S. Defense Department contract will be used to continue NanoBio’s development of its antimicrobial nanoemulsions, which incorporate nanoparticles for biodefense and drug delivery applications.


The company also has formed a new firm, NanoCure Corp., to commercialize dendrimer-based drug-delivery and imaging platforms. Funded by state and federal grants, NanoCure is preparing to have technology ready for clinical trials within two years, according to a company news release.


NanoBio and NanoCure are developing technology licensed from University of Michigan’s Center for Biologic Nanotechnology.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.